Ignite Creation Date:
2025-12-24 @ 6:39 PM
Ignite Modification Date:
2026-02-07 @ 3:01 PM
Study NCT ID:
NCT02049957
Status:
COMPLETED
Last Update Posted:
2023-02-08
First Post:
2013-12-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Sponsor:
Calithera Biosciences, Inc
Organization: